Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia by Elbedewy TA, Elsebaey MA, Elshweikh SA, Elashry H, Abd-Elsalam S

Get full text

Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience by Elbedewy TA, Elsebaey MA, Elkholy RA, Tahoon DM, Elshweikh SA

Get full text

Galectin-3 as a prognostic biomarker for diabetic nephropathy by Hodeib H, Hagras MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, Elsebaey MA, Elshweikh SA

Get full text

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection by Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S

Get full text